Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bullens

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug formC J Refino, N B Modi, S Bullens, et al.
Journal of Medicinal Chemistry|May 29, 1992
Cyclic RGD peptide analogues as antiplatelet antithromboticsP L Barker, S Bullens, S Bunting, et al.
Thrombosis and Haemostasis|April 20, 2001
Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeuticL Presta, P Sims, Y G Meng, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug formC J Refino, N B Modi, S Bullens, et al.
Journal of Medicinal Chemistry|May 29, 1992
Cyclic RGD peptide analogues as antiplatelet antithromboticsP L Barker, S Bullens, S Bunting, et al.
Thrombosis and Haemostasis|April 20, 2001
Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeuticL Presta, P Sims, Y G Meng, et al.
Pageof 1